OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020
James A. Karlowsky, Sibylle Lob, C Andrew DeRyke, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 5
Open Access | Times Cited: 29
James A. Karlowsky, Sibylle Lob, C Andrew DeRyke, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 5
Open Access | Times Cited: 29
Showing 1-25 of 29 citing articles:
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo, et al.
Clinical Infectious Diseases (2023)
Open Access | Times Cited: 476
Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo, et al.
Clinical Infectious Diseases (2023)
Open Access | Times Cited: 476
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections
Pranita D. Tamma, Emily L. Heil, Julie Ann Justo, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 135
Pranita D. Tamma, Emily L. Heil, Julie Ann Justo, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 135
Novel Antimicrobial Agents for Gram-Negative Pathogens
Marios Karvouniaris, Maria Panagiota Almyroudi, Mohd H. Abdul‐Aziz, et al.
Antibiotics (2023) Vol. 12, Iss. 4, pp. 761-761
Open Access | Times Cited: 21
Marios Karvouniaris, Maria Panagiota Almyroudi, Mohd H. Abdul‐Aziz, et al.
Antibiotics (2023) Vol. 12, Iss. 4, pp. 761-761
Open Access | Times Cited: 21
Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa
Stefanos Ferous, Cleo Anastassopoulou, Vassiliki Pitiriga, et al.
Antibiotics (2024) Vol. 13, Iss. 3, pp. 285-285
Open Access | Times Cited: 6
Stefanos Ferous, Cleo Anastassopoulou, Vassiliki Pitiriga, et al.
Antibiotics (2024) Vol. 13, Iss. 3, pp. 285-285
Open Access | Times Cited: 6
Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases
Marianna Meschiari, Antoine Asquier-Khati, Giusy Tiseo, et al.
International Journal of Antimicrobial Agents (2024) Vol. 64, Iss. 1, pp. 107186-107186
Closed Access | Times Cited: 6
Marianna Meschiari, Antoine Asquier-Khati, Giusy Tiseo, et al.
International Journal of Antimicrobial Agents (2024) Vol. 64, Iss. 1, pp. 107186-107186
Closed Access | Times Cited: 6
Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report
Dilip Dubey, Manish Roy, Tajamul Hussain Shah, et al.
Annals of Clinical Microbiology and Antimicrobials (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 15
Dilip Dubey, Manish Roy, Tajamul Hussain Shah, et al.
Annals of Clinical Microbiology and Antimicrobials (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 15
In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis
Siquan Shen, Chengkang Tang, Weiwei Yang, et al.
Emerging Microbes & Infections (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Siquan Shen, Chengkang Tang, Weiwei Yang, et al.
Emerging Microbes & Infections (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)
Hélio S. Sader, Rodrigo E. Mendes, S J Ryan Arends, et al.
BMC Pulmonary Medicine (2025) Vol. 25, Iss. 1
Open Access
Hélio S. Sader, Rodrigo E. Mendes, S J Ryan Arends, et al.
BMC Pulmonary Medicine (2025) Vol. 25, Iss. 1
Open Access
Benchmarking antimicrobial use to antimicrobial resistance: a comparative study of two hospitals using current National Healthcare Safety Network (NHSN) metrics
Carlos A.Q. Santos, Sarah Won, Ryan Dwyer, et al.
Infection Control and Hospital Epidemiology (2025), pp. 1-8
Closed Access
Carlos A.Q. Santos, Sarah Won, Ryan Dwyer, et al.
Infection Control and Hospital Epidemiology (2025), pp. 1-8
Closed Access
β-Lactamase diversity in Pseudomonas aeruginosa
Andrew R. Mack, Andrea M. Hujer, María F. Mojica, et al.
Antimicrobial Agents and Chemotherapy (2025) Vol. 69, Iss. 3
Open Access
Andrew R. Mack, Andrea M. Hujer, María F. Mojica, et al.
Antimicrobial Agents and Chemotherapy (2025) Vol. 69, Iss. 3
Open Access
Management strategies for severe Pseudomonas aeruginosa infections
Hermann Do Rego, Jean‐François Timsit
Current Opinion in Infectious Diseases (2023) Vol. 36, Iss. 6, pp. 585-595
Closed Access | Times Cited: 9
Hermann Do Rego, Jean‐François Timsit
Current Opinion in Infectious Diseases (2023) Vol. 36, Iss. 6, pp. 585-595
Closed Access | Times Cited: 9
Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli
Lili Tao, Ashley Dahlquist, Harley Harris, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 10
Closed Access | Times Cited: 3
Lili Tao, Ashley Dahlquist, Harley Harris, et al.
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 10
Closed Access | Times Cited: 3
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study
Ryan K. Shields, Lilian M. Abbo, Renee Ackley, et al.
The Lancet Infectious Diseases (2024)
Closed Access | Times Cited: 3
Ryan K. Shields, Lilian M. Abbo, Renee Ackley, et al.
The Lancet Infectious Diseases (2024)
Closed Access | Times Cited: 3
Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
Baharak Babouee Flury, Anja Bösch, Valentin Gisler, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
Baharak Babouee Flury, Anja Bösch, Valentin Gisler, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
Ryan K. Shields, Emre Yücel, Vladimir Turzhitsky, et al.
Journal of Global Antimicrobial Resistance (2024) Vol. 37, pp. 190-194
Open Access | Times Cited: 2
Ryan K. Shields, Emre Yücel, Vladimir Turzhitsky, et al.
Journal of Global Antimicrobial Resistance (2024) Vol. 37, pp. 190-194
Open Access | Times Cited: 2
Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms
Christina Koenig, Joseph L. Kuti
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2024) Vol. 44, Iss. 8, pp. 658-674
Closed Access | Times Cited: 2
Christina Koenig, Joseph L. Kuti
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2024) Vol. 44, Iss. 8, pp. 658-674
Closed Access | Times Cited: 2
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa
Christian M Gill, David P. Nicolau, Elif Aktaş, et al.
Journal of Antimicrobial Chemotherapy (2022) Vol. 78, Iss. 1, pp. 252-256
Open Access | Times Cited: 9
Christian M Gill, David P. Nicolau, Elif Aktaş, et al.
Journal of Antimicrobial Chemotherapy (2022) Vol. 78, Iss. 1, pp. 252-256
Open Access | Times Cited: 9
Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials
Tim Yi-Ting Chen, Chi‐Kuei Hsu, Shun-Chuan Shih, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106844-106844
Closed Access | Times Cited: 5
Tim Yi-Ting Chen, Chi‐Kuei Hsu, Shun-Chuan Shih, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106844-106844
Closed Access | Times Cited: 5
Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates—SMART United States 2019–21
James A. Karlowsky, Sibylle Lob, Karri A. Bauer, et al.
JAC-Antimicrobial Resistance (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 5
James A. Karlowsky, Sibylle Lob, Karri A. Bauer, et al.
JAC-Antimicrobial Resistance (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 5
Susceptibility profile and β-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam—SMART 2016–21
James A. Karlowsky, Sibylle Lob, Mark Estabrook, et al.
JAC-Antimicrobial Resistance (2023) Vol. 5, Iss. 3
Open Access | Times Cited: 4
James A. Karlowsky, Sibylle Lob, Mark Estabrook, et al.
JAC-Antimicrobial Resistance (2023) Vol. 5, Iss. 3
Open Access | Times Cited: 4
Computing antimicrobial use/antimicrobial resistance ratios: A novel way to assess inpatient antimicrobial utilization using current National Healthcare Safety Network metrics
Carlos A.Q. Santos, Ashley I. Martinez, Sarah Won, et al.
Transplant Infectious Disease (2022) Vol. 24, Iss. 5
Open Access | Times Cited: 6
Carlos A.Q. Santos, Ashley I. Martinez, Sarah Won, et al.
Transplant Infectious Disease (2022) Vol. 24, Iss. 5
Open Access | Times Cited: 6
Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling
Luc Deroche, Vincent Aranzana‐Climent, Albane Rozenholc, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 10
Open Access | Times Cited: 3
Luc Deroche, Vincent Aranzana‐Climent, Albane Rozenholc, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 10
Open Access | Times Cited: 3
Natural protein engineering in the Ω-loop: the role of Y221 in ceftazidime and ceftolozane resistance in Pseudomonas -derived cephalosporinase
Andrew R. Mack, Vijay Kumar, Magdalena A. Taracila, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 11
Open Access | Times Cited: 3
Andrew R. Mack, Vijay Kumar, Magdalena A. Taracila, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 11
Open Access | Times Cited: 3
Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis
Reza Abniki, Amirhossein Tashakor, Melika Masoudi, et al.
Current Therapeutic Research (2023) Vol. 100, pp. 100723-100723
Open Access | Times Cited: 3
Reza Abniki, Amirhossein Tashakor, Melika Masoudi, et al.
Current Therapeutic Research (2023) Vol. 100, pp. 100723-100723
Open Access | Times Cited: 3
Real-world in vitro activity of newer antibiotics against Enterobacterales and Pseudomonas aeruginosa , including carbapenem-non-susceptible and multidrug-resistant isolates: a multicenter analysis
Todd Riccobene, ChinEn Ai, Kalvin Yu, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 3
Todd Riccobene, ChinEn Ai, Kalvin Yu, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 3
